Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements-Reference-Cited by-同舟云学术

Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements

Published:2021-12-29 Issue: Volume: Page:1-11
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Cantini Fabrizio¹,Goletti Delia²^ORCID,Benucci Maurizio³,Foti Rosario⁴,Damiani Arianna⁵,Niccoli Laura¹

Affiliation:

1. Rheumatology Department, Hospital of Prato, Prato Italy

2. Translational Research Unit, Department of Epidemiology and Preclinical Research, “L. Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS, Via,Portuense 292, 00149 Rome, Italy

3. Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy

4. Rheumatology Unit, Vittorio-Emanuele University Hospital of Catania, Catania, Italy

5. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2020247

Reference142 articles.

1. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

2. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics